- Home
- HLVX vs APLT Comparison
HLVX vs APLT Comparison
Compare HLVX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- APLT
- Stock Information
- Founded
- HLVX 2020
- APLT 2016
- Country
- HLVX United States
- APLT United States
- Employees
- HLVX N/A
- APLT N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- APLT Health Care
- Exchange
- HLVX Nasdaq
- APLT Nasdaq
- Market Cap
- HLVX 83.7M
- APLT 80.3M
- IPO Year
- HLVX 2022
- APLT 2019
- Fundamental
- Price
- HLVX $1.46
- APLT $0.41
- Analyst Decision
- HLVX Hold
- APLT Buy
- Analyst Count
- HLVX 5
- APLT 7
- Target Price
- HLVX $2.33
- APLT $6.10
- AVG Volume (30 Days)
- HLVX 152.5K
- APLT 1.6M
- Earning Date
- HLVX 03-28-2025
- APLT 05-08-2025
- Dividend Yield
- HLVX N/A
- APLT N/A
- EPS Growth
- HLVX N/A
- APLT N/A
- EPS
- HLVX N/A
- APLT N/A
- Revenue
- HLVX N/A
- APLT N/A
- Revenue This Year
- HLVX N/A
- APLT N/A
- Revenue Next Year
- HLVX N/A
- APLT $2,426.33
- P/E Ratio
- HLVX N/A
- APLT N/A
- Revenue Growth
- HLVX N/A
- APLT N/A
- 52 Week Low
- HLVX $1.37
- APLT $0.43
- 52 Week High
- HLVX $16.31
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- HLVX 31.43
- APLT 33.27
- Support Level
- HLVX $1.37
- APLT $0.45
- Resistance Level
- HLVX $1.54
- APLT $0.56
- Average True Range (ATR)
- HLVX 0.08
- APLT 0.05
- MACD
- HLVX -0.02
- APLT -0.00
- Stochastic Oscillator
- HLVX 21.69
- APLT 5.79
Stock Price Comparison Chart: HLVX vs APLT
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.